Proteomics Study of Mild Cognitive Impairment and Alzheimer's Disease
Trial Parameters
Brief Summary
This study intends to adopt standardized and rigorous cross-sectional research, collect biological specimens (including blood, feces, urine, saliva and tongue coating) from eligible subjects, and use liquid chromatography/mass spectrometry (LC-MS/MS) technology to explore early warning indicators of protein in patients with mild cognitive impairment and Alzheimer's disease
Eligibility Criteria
Inclusion Criteria: 1. Older than 55-year-old，male or female. 2. patients meet the diagnosis of mild cognitive impairment (MCI) or Alzheimer's disease(AD) or whose family members were diagnoed with AD 3. Complete self-rating scale for memory impairment (AD-8 scale) 4. Those who agree to participate in clinical research and sign informed consent. Exclusion Criteria: 1. Patients with acute cardiovascular and cerebrovascular diseases, acute infections (pneumonia, urinary tract infection, oral infection, digestive tract infection), severe renal dysfunction, and uremia; 2. Pregnant or lactating women;